Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen

Alemtuzumab, fludarabine, and melphalan reduced-intensity conditioning (RIC) regimens are increasingly used for the hematopoietic cell transplantation (HCT) of pediatric and young adult patients with nonmalignant diseases. Early experience suggests that these regimens are associated with good surviv...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Biol Blood Marrow Transplant
Huvudupphovsmän: Marsh, Rebecca A., Rao, Marepalli B., Gefen, Aharon, Bellman, Denise, Mehta, Parinda A., Khandelwal, Pooja, Chandra, Sharat, Jodele, Sonata, Myers, Kasiani C., Grimley, Michael, Dandoy, Christopher, El-Bietar, Javier, Kumar, Ashish R., Leemhuis, Tom, Zhang, Kejian, Bleesing, Jack J., Jordan, Michael B., Filipovich, Alexandra H., Davies, Stella M.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2015
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4603747/
https://ncbi.nlm.nih.gov/pubmed/25865646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2015.04.009
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk